Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 12319
Country/Region: Ethiopia
Year: 2017
Main Partner: Federal Police Commission - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $915,877 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $36,749
Care: TB/HIV (HVTB) $48,017
Care: Pediatric Care and Support (PDCS) $7,772
Laboratory Infrastructure (HLAB) $15,200
Strategic Information (HVSI) $16,388
Testing: HIV Testing and Counseling (HVCT) $46,386
Sexual Prevention: Other Sexual Prevention (HVOP) $408,823
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $5,248
Treatment: Adult Treatment (HTXS) $313,066
Treatment: Pediatric Treatment (PDTX) $18,228
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 30
GEND_GBV Number of people receiving post-GBV care 2018 50
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 17,498
PMTCT_ART Already on ART at beginning of current pregnancy 2018 26
PMTCT_ART New on ART 2018 14
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 40
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,106
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 48
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 9
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 37
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 1
PMTCT_STAT By Age (Numerator): 15-19 2018 105
PMTCT_STAT By Age (Numerator): 20-24 2018 737
PMTCT_STAT By Age (Numerator): 25-49 2018 1,264
PMTCT_STAT By Number of known positives: 15-19 2018 1
PMTCT_STAT By Number of known positives: 20-24 2018 10
PMTCT_STAT By Number of known positives: 25-49 2018 16
PMTCT_STAT By Number of new negative: 15-19 2018 103
PMTCT_STAT By Number of new negative: 20-24 2018 722
PMTCT_STAT By Number of new negative: 25-49 2018 1,239
PMTCT_STAT By Number of new positives: 15-19 2018 1
PMTCT_STAT By Number of new positives: 20-24 2018 5
PMTCT_STAT By Number of new positives: 25-49 2018 9
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,106
PMTCT_STAT_den By Age (Denominator): <15-19 2018 105
PMTCT_STAT_den By Age (Denominator): 20-24 2018 737
PMTCT_STAT_den By Age (Denominator): 25-49 2018 1,264
PP_PREV Age/sex: 15-19 Male 2018 31
PP_PREV Age/sex: 20-24 Female 2018 920
PP_PREV Age/sex: 20-24 Male 2018 9,461
PP_PREV Age/sex: 25-49 Female 2018 751
PP_PREV Age/sex: 25-49 Male 2018 8,745
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 19,908
PP_PREV Sum of Age/Sex disaggregates 2018 19,908
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 10
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 17
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 17
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 10
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 3
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 60
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 6
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 149
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 218
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 222
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 3
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 61
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 6
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 152
TX_CURR Aggregated Age/Sex: <15 Female 2018 78
TX_CURR Aggregated Age/Sex: <15 Male 2018 82
TX_CURR Aggregated Age/Sex: 15+ Female 2018 1,528
TX_CURR Aggregated Age/Sex: 15+ Male 2018 1,018
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,706
TX_CURR Sum of Aggregated Age/Sex <15 2018 160
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 2,546
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 2,706
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 7
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 7
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 86
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 129
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 229
TX_NEW Pregnancy status 2018 14
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 229
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 2,667
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 2,250
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 29
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 13
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 30
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 14
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,100
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 199
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 733
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 132
TX_PVLS Numerator: Indication: Routine 2018 1,892
TX_PVLS Numerator: Indication: Targeted 2018 358
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 19
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 5
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 41
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 18
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 43
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 18
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,222
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 306
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 815
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 204
TX_PVLS_den Denominator: Indication: Routine 2018 2,121
TX_PVLS_den Denominator: Indication: Targeted 2018 546
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 21
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 5
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 7
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 111
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 74
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 198
TX_RET Numerator by Status: Pregnant 2018 23
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 219
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 123
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 82
TX_RET_den Denominator by Status: Pregnant 2018 26
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 7,306
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 117
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 3
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 41
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 69
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 167
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 272
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 2,609
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 4,258
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 98
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 8
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 25
TX_TB_den Denominator: By Screen Result: Negative 2018 7,160
TX_TB_den Denominator: By Screen Result: Positive 2018 146
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 131
Cross Cutting Budget Categories and Known Amounts Total: $57,874
Gender: Gender Based Violence (GBV) $12,000
GBV Prevention
Implementation
Capacity building
Renovation $42,743
Water $3,131